Skip to main content
Premium Trial:

Request an Annual Quote

IntegraGen Theranostic Test for Colorectal Cancer Gets CE-IVD Mark

NEW YORK (GenomeWeb) – IntegraGen today announced that its test kit for predicting patient response to anti-EGFR therapy has been CE-IVD marked, and the company will launch it in the European Union.

The test, miRpredX 31-3p, is a positive theranostic test for patients with metastatic colorectal cancer that quantifies the expression of miR-31-3p in formalin-fixed, paraffin-embedded tumor samples using standard quantitative reverse-transcription PCR, IntegraGen said. It added that miRpredX 31-3p predicts the potential clinical benefits associated with first-line anti-EGFR therapy compared to anti-VEGF therapy, or when second or additional lines of treatment with an anti-EGFR therapy is beneficial, compared to chemotherapy by itself, for patients with RAS wild-type mCRC.

A recent study demonstrated the utility of miR-31-3p expression as a predictive marker for overall survival and response to anti-EGFR therapy treatment, Évry, France-based IntegraGen said.

Achieving CE-IVD marking follows five years of development work and clinical validation of the test, IntegraGen Director of Molecular Diagnostics Yann Gaston-Mathé said in a statement. He added that the worldwide market for miR-31-3p testing is estimated to be $150 million. 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.